COG A Phase III Study of Risk Directed Therapy for Infants with Acute Lymphoblastic Leukemia (ALL): Randomization of Highest Risk Infants to Intensive Chemotherapy FLT3 Inhibition (CEP-701; Lestaurtinib; IND#76431; NSC#617807) Pediatric CIRB Closed to Accrual. Pts Still Rcving Intervention Available to Open